https://www.optimumcomms.com/wp-content/uploads/2023/02/Biocomposites_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-10-16 08:30:052024-10-16 08:29:08Biocomposites invests in InfectoTest GmbH – developers of a bacterial-specific point-of-care test for periprosthetic joint infection (PJI)
https://www.optimumcomms.com/wp-content/uploads/2023/02/Biocomposites_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-10-16 08:30:052024-10-16 08:29:08Biocomposites invests in InfectoTest GmbH – developers of a bacterial-specific point-of-care test for periprosthetic joint infection (PJI)
Commit Biologics appoints Mikkel Wandahl Pedersen as Chief Scientific Officer
Highly experienced leader with demonstrated track record…

Novo Holdings to acquire majority stake in Stingray Marine Solutions, a leading provider of aquaculture technology
Novo Holdings today announced that it has agreed to acquire…

Novo Holdings Launches Portfolio Company Booster Therapeutics to Advance New Class of Small Molecule Proteasome Activator Therapeutics
Booster Therapeutics raises $15 million seed financing led…

Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2024
HDP-101 clinical trial in Europe and US continues with adjusted…

STORM Therapeutics to Present Phase 1 Data on its First-in-Class Lead Product STC-15 at EORTC-NCI-AACR Symposium
STC-15 is the first METTL3 inhibitor to enter clinical development
Presentation…

Antag Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Lead Molecule, AT-7687
Copenhagen, Denmark – October 9, 2024 – Antag Therapeutics,…

Curve Therapeutics continues to enhance leadership team with appointment of Rab Prinjha as Chief R&D Officer
Deep expertise in leading drug discovery programs across…

Adcendo Announces US FDA Clearance of IND Application for Phase I/II First-in-Human ADCElerate-01 Trial of ADCE-D01 (uPARAP Receptor Targeting ADC) Trial in Patients with Metastatic and/or Unresectable Soft Tissue Sarcoma (STS)
ADCE-D01 is a first-in-class antibody-drug conjugate (ADC)…

Resolution Therapeutics Announces £63.5 Million Series B Financing and Chair Appointment
Financing to advance lead asset RTX001, an engineered, pro-regenerative…

LoQus23 Therapeutics announces £35 million (c.$43 million) Series A financing to advance its small molecule somatic expansion inhibition therapy for Huntington’s disease
Financing led by leading life sciences venture capital firm…

Curve Therapeutics further strengthens leadership team with the appointment of Andre Hoekema as new Chair of Board
Dr Hoekema brings over four decades of successful biotech…

Heidelberg Pharma: New Clinical Data on Lead ADC Candidate HDP-101 Presented at IMS 2024 Demonstrating Complete Remission in One Patient
Data from the study with the lead ADC candidate, HDP-101,…

Resolution Therapeutics Announces Upcoming Presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2024
– Oral Presentation of complete data from the three-year MATCH…

Neuraxpharm expands operations into the Middle East
Brings leading CNS products, including BRIUMVI® (ublituximab),…

AstronauTx appoints Jane Rhodes as Chief Executive Officer and Expands Executive Team
Jane Rhodes appointed as Chief Executive Officer
Magnus…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York